Ono Announces Encouraging Efficacy Signals Of ONO-2808, A S1P5 Receptor Agonist, In An Interim Analysis Of Ongoing Phase 2 Clinical Trial In Patients With Multiple System Atrophy

Reuters
2025.10.09 12:20
portai
I'm PortAI, I can summarize articles.

Ono Pharmaceutical Co Ltd :ONO ANNOUNCES ENCOURAGING EFFICACY SIGNALS OF ONO-2808, A S1P5 RECEPTOR AGONIST, IN AN INTERIM ANALYSIS OF ONGOING PHASE 2 CLINICAL TRIAL IN PATIENTS WITH MULTIPLE SYSTEM ATROPHYONO PHARMACEUTICAL: MSA TENDED TO BE SLOWER IN ONO-2808 GROUP IN TERMS OF CLINICAL OUTCOME ENDPOINTONO PHARMACEUTICAL CO LTD: ALL DOSES WERE WELL TOLERATED WITH MANAGEABLE SAFETY PROFILE

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.